Smith & Nephew (SNN) Q2 2026 Earnings Call Transcript

Smith & Nephew reported $566M trading profit in 1H (margin 18.3%, +60 bps) and +11% adjusted EPS to $0.48, but cut full-year 2026 underlying revenue growth outlook to ~4% from prior expectations due to U.S. Orthopaedics (knees -1% underlying) and Advanced Wound Bioactives (SANTYL -12.7% in the quarter) headwinds. Management maintained profit and free-cash-flow guidance, targeting ~8% trading profit growth excluding M&A and ~$800M free cash flow, supported by stepped efficiency savings to ~$200M (vs. prior ~$150M) and broadly neutral tariffs net of refunds. Net debt was ~$3B (including a $500M buyback program), while 2H revenue is guided to +5% to +5.5%—with growth phasing aided by the late-Q3/early-Q4 LANDMARK launch and an extra trading day in Q4.

Analysis

The near-term winner is not the stock; it is the larger medtech platforms that can use reimbursement complexity and ortho SKU churn to steal share. Smith & Nephew is showing that cost discipline can mask revenue softness, but that also tells you where the competitive damage is landing: knees and wound are being constrained by portfolio gaps and administrative friction, while sports med is doing the heavy lifting. Second-order, if management keeps leaning on manufacturing/procurement savings, the pressure shifts to distributors, reps, and lower-tier suppliers first, which tends to favor scale players with broader service bundles and stronger surgeon lock-in.

The main catalyst is whether the second-half inflection actually appears in the next 1-2 quarters. If LANDMARK and the robotics pipeline do not translate into visible deployment acceleration, the market will likely stop underwriting the 2027 growth narrative and re-rate the name on the lower 2026 base. The bigger tail risk is reimbursement spillover: prior auth on SANTYL and CMS-driven skin substitute disruption can linger for months, not weeks, and can force a second round of estimate cuts if channel normalization is slower than management expects.

Contrarian view: the market may be underestimating how far earnings and cash flow can still hold up even with weak top-line momentum, given buybacks, inventory reduction, and margin expansion. But that is a bridge, not a moat; if revenue recovery slips, multiple expansion is hard to defend because this remains an execution-sensitive device business, not a structurally recurring growth compounder. The burden of proof has shifted from story to evidence: sequential improvement in Q3, not just a better-looking Q4 denominator, is what matters.

Key Decisions for Investors

• Short SNN on any 3%+ post-earnings bounce; 1-3 month horizon. Risk/reward favors fading relief rallies until Q3 sequential revenue improvement is visible. Cover if management shows clear order/deployment acceleration in LANDMARK or if Q3 growth materially outpaces the implied low-single-digit run-rate.
• Pair trade: long SYK / short SNN for 3-6 months. Express the view that ortho share shifts and robotics adoption favor the cleaner execution story, while SNN remains exposed to knee portfolio gaps and reimbursement friction. Thesis breaks if SNN demonstrates sustained high-single-digit organic acceleration in orthopaedics by the next print.
• No aggressive long here; set an alert, not a recommendation, for Q3 signs of skin substitute stabilization and SANTYL prior-auth normalization. If those do not improve by the next quarter, the 2027 growth bridge becomes less credible.
• For market beta exposure, prefer diversified medtech exposure over single-name SNN until reimbursement noise clears; avoid expressing a structural bullish view in SNN via options because the catalyst path is binary and dependent on operational follow-through.